Patents by Inventor Karin Benz

Karin Benz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11324855
    Abstract: A cell-free combination for use in the controlled, especially decelerated or retarded, release of active ingredient and/or in the production of a formulation in hydrogel form, especially depot formulation in hydrogel form, and/or as a formulation in hydrogel form, especially depot formulation in hydrogel form, and/or for the coating of a medical product, especially implant, preferably with a formulation in hydrogel form, especially depot formulation in hydrogel form, wherein the cell-free combination comprises a first component and a second component, the first component comprising crosslinkable albumin and the second component comprising a crosslinking agent for the albumin. Additionally, a hydrogel-forming material or hydrogel, to a kit or multicomponent system, to a medical product or a pharmaceutical formulation, to a discharge device, and to uses of the cell-free combination and of the hydrogel-forming material or hydrogel.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: May 10, 2022
    Assignee: TETEC Tissue Engineering Technologies AG
    Inventors: Christoph Gaissmaier, Nils Clausen, Karin Benz
  • Publication number: 20200147263
    Abstract: A cell-free combination for use in the controlled, especially decelerated or retarded, release of active ingredient and/or in the production of a formulation in hydrogel form, especially depot formulation in hydrogel form, and/or as a formulation in hydrogel form, especially depot formulation in hydrogel form, and/or for the coating of a medical product, especially implant, preferably with a formulation in hydrogel form, especially depot formulation in hydrogel form, wherein the cell-free combination comprises a first component and a second component, the first component comprising crosslinkable albumin and the second component comprising a crosslinking agent for the albumin. Additionally, a hydrogel-forming material or hydrogel, to a kit or multicomponent system, to a medical product or a pharmaceutical formulation, to a discharge device, and to uses of the cell-free combination and of the hydrogel-forming material or hydrogel.
    Type: Application
    Filed: April 24, 2018
    Publication date: May 14, 2020
    Inventors: Christoph Gaissmaier, Nils Clausen, Karin Benz
  • Patent number: 10539574
    Abstract: A method for the in vitro detection of cartilage tissue and/or for the in vitro determination of the purity of cartilage tissue includes: a) treating a tissue sample with a protease and b) testing the protease-treated tissue sample for the presence of protease-resistant fragments of type II collagen and/or type I collagen. Methods can be carried out for preparing a cartilage cell culture, and for preparing a cartilage cell-loaded implant. Protease-resistant fragments of type II collagen and/or type I collagen can be used for the in vitro detection of cartilage tissue and/or for the in vitro determination of the purity of cartilage tissue. A kit can be used for carrying out the methods.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: January 21, 2020
    Assignee: TETEC Tissue Engineening Technologies AG
    Inventors: Karin Benz, Christian Freudigmann, Christoph Gaissmaier, Jochen Hecky, Jürgen Mollenhauer
  • Patent number: 10500154
    Abstract: The invention relates to an injectable biocompatible composition based on a polymeric support as well as to a method for producing it, which composition which comprises at least one hydrophilic polymer, wherein the polymer is polymerizable in situ to form a gel, and wherein the hydrophilic polymer is crosslinkable serum albumin or crosslinkable serum protein. The composition can be used in the restoration, the reconstruction, and/or the replacement of tissues and/or organs, or as a drug release implant in mammals. The composition is particularly suitable for treating cartilage disorders of a diseased or injured articular site in a mammal.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: December 10, 2019
    Assignee: NMI NATURWISSENSCHAFTLICHES UND MEDIZINISCHES INSTITUT AN DER UNIVERSITAET TUEBINGEN
    Inventors: Juergen Mollenhauer, Karin Benz, Barbara Platz, Helmut Wurst, Reinout Stoop
  • Publication number: 20190161799
    Abstract: The use of a marker for determining the composition or purity of a cell culture, wherein the marker is at least one marker selected from the group consisting of MMP1, ACE, POSTN, SYNPO, SULF1, ARH-GEF28, IGF2BP1, BAIAP2L1, LIMCH1, SCIN, DCLK1, PPL, CRABP2, NES, XPNPEP2 and SLIT3, and the expression level of the at least one marker is determined.
    Type: Application
    Filed: July 25, 2017
    Publication date: May 30, 2019
    Inventors: Karin Benz, Christoph Gaissmaier
  • Publication number: 20190154703
    Abstract: The invention relates to markers for use in vitro in the prognosis of a clinical outcome (outcome prognosis) of an autologous disc cell transplantation, in the progress assessment/progress monitoring of an autologous disc cell transplantation, in the assessment of the quality of intervertebral disc cells, in the assessment of the quality of an implant and/or advanced therapy medicinal products (ATMP) for the treatment of an intervertebral disc defect, and/or in the diagnosis of an intervertebral disc and/or spinal column defect and a corresponding in vitro method.
    Type: Application
    Filed: April 25, 2017
    Publication date: May 23, 2019
    Applicant: TETEC Tissue Engineering Technologies AG
    Inventors: Christoph GAISSMAIER, Karin BENZ, Bernd ROLAUFFS
  • Patent number: 9828636
    Abstract: An in vitro method of prognostically assessing tissue regeneration capacity and/or cellular potency and/or the prospects of success of an implantation and/or transplantation, wherein the transcriptome and/or the gene expression of cells, the gene expression originating from the transcriptome, are analyzed.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: November 28, 2017
    Assignee: TETEC Tissue Engineering Technologies AG
    Inventors: Jürgen Mollenhauer, Christoph Gaissmaier, Karin Benz
  • Publication number: 20170261515
    Abstract: A method for the in vitro detection of cartilage tissue and/or for the in vitro determination of the purity of cartilage tissue includes: a) treating a tissue sample with a protease and b) testing the protease-treated tissue sample for the presence of protease-resistant fragments of type II collagen and/or type I collagen. Methods can be carried out for preparing a cartilage cell culture, and for preparing a cartilage cell-loaded implant. Protease-resistant fragments of type II collagen and/or type I collagen can be used for the in vitro detection of cartilage tissue and/or for the in vitro determination of the purity of cartilage tissue. A kit can be used for carrying out the methods.
    Type: Application
    Filed: July 10, 2015
    Publication date: September 14, 2017
    Inventors: Karin Benz, Christian Freudigmann, Christoph Gaissmaier, Jochen Hecky, Jürgen Mollenhauer
  • Publication number: 20160046989
    Abstract: An in vitro method of prognostically assessing tissue regeneration capacity and/or cellular potency and/or the prospects of success of an implantation and/or transplantation, wherein the transcriptome and/or the gene expression of cells, said gene expression originating from the transcriptome, are analyzed.
    Type: Application
    Filed: March 20, 2014
    Publication date: February 18, 2016
    Inventors: Jürgen Mollenhauer, Christoph Gaissmaier, Karin Benz
  • Publication number: 20100322993
    Abstract: The invention relates to an injectable biocompatible composition based on a polymeric support as well as to a method for producing it, which composition which comprises at least one hydrophilic polymer, wherein the polymer is polymerizable in situ to form a gel, and wherein the hydrophilic polymer is crosslinkable serum albumin or crosslinkable serum protein. The composition can be used in the restoration, the reconstruction, and/or the replacement of tissues and/or organs, or as a drug release implant in mammals. The composition is particularly suitable for treating cartilage disorders of a diseased or injured articular site in a mammal.
    Type: Application
    Filed: July 27, 2010
    Publication date: December 23, 2010
    Inventors: Juergen Mollenhauer, Karin Benz, Barbara Platz, Helmut Wurst, Reinout Stoop